Tamoxifen
What's New
Last Posted: Aug 30, 2021
- Machine Learning to Predict Tamoxifen Nonadherence Among US Commercially Insured Patients With Metastatic Breast Cancer.
Yerrapragada Gayathri et al. JCO clinical cancer informatics 2021 8 814-825 - Young women's decision-making and experience of using tamoxifen to reduce BRCA1/2 breast cancer risk: a qualitative study.
Forrest Laura E et al. Psycho-oncology 2020 Oct - A Patient's Guide to Endometrial Cancer-This cancer is on the rise. But early detection saves lives.
MO Shroeder, US News, October 4, 2019 - Medication Use to Reduce Risk of Breast Cancer- US Preventive Services Task Force Recommendation Statement
USPSTF Recommendation, JAMA, September 3, 2019 - Artificial intelligence reveals new breast cancer types that respond differently to treatment
Institute of Cancer Research, August 2019 - Population DNA testing for disease risk is coming. Here are five things to know,
by Paul Lacaze and Jane Tiller, The Conversation, May 23, 2019 - Management of Individuals at Increased Hereditary Risk
ASCO, 2018 - Local Coverage Determination (LCD): Biomarkers Overview (L35062)
The U.S. Centers for Medicare & Medicaid Services - CLINGEN Actionability Report for Breast Cancer - ATM, CHEK2
ClinGen Actionability Working Group - CLINGEN Actionability Report for Familial Adenomatous Polyposis - APC
ClinGen Actionability Working Group - CLINGEN Actionability Report for Peutz-Jeghers Syndrome - STK11
ClinGen Actionability Working Group - Cancer Scientists Have Ignored African DNA in the Search for Cures
J Wapner, Newsweek, July 2018 - Good News for Women With Breast Cancer: Many Dont Need Chemo
D Grady, NY Times, June 2, 2018 - Tailoring Chemotherapy Decisions TAILORx Study Results
DJ Attai, Blog, June 4, 2018 - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018)
÷
M Goetz et al, Clin Pharm Thera, Jan 2018 - New international practice guidelines for tamoxifen treatment based on CYP2D6 genotype
Mayo Clinic, Feb 2018 - Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.
Wigle Theodore J et al. Journal of personalized medicine 2017 Dec (4) - Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene
A Novillo et al, Pharmacogenomics Journal, October 4, 2016 - Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study.
Kovac Mirjana et al. Eur. J. Intern. Med. 2015 Jan (1) 63-7
About RCH PHGKB
Reproductive and Child Health PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to reproductive and child Health...more
Content Summary
Common RCH Related Topics
- Attention Deficit/Hyperactivity Disorder
- Autism
- Birth Defects
- Carrier Testing
- Cerebral Palsy
- Congenital heart defects
- Pregnancy loss
- Developmental Disabilities
- Gestational Diabetes
- Hearing loss
- Neural tube defects
- Infant Mortality
- Infertility
- Learning disability
- Newborn Screening
- Preeclampsia
- Prematurity
- Prenatal Testing
- Stillbirth
- Sudden Infant Death Syndrome
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: